Neko Health Raises $700M Series C Ahead of U.S. Expansion

Neko Health has raised a $700M Series C as the Stockholm-based preventive health company prepares to open its first U.S. clinics, beginning in New York before expanding into additional cities. The financing is a bet that AI-enabled diagnostics, proprietary medical hardware, and clinic operations can shift healthcare economics toward earlier detection before illness requires more expensive intervention.

What Happened

Neko Health announced its $700M Series C, led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD Partners.

The company said the financing will accelerate international expansion, continue investment in proprietary technology, and support its U.S. market entry. The first clinic is expected to open in New York, providing Neko Health with its first large-scale test inside the U.S. healthcare market, where preventive care, patient experience, and diagnostic economics intersect.

Founded in 2018 by Hjalmar Nilsonne and Daniel Ek, Neko Health has spent years building a vertically integrated preventive healthcare platform rather than a standalone medical device or software product. Its model combines proprietary hardware, software, AI analysis, clinical operations, and same-day clinician consultations into a single patient experience.

Why Neko Health Matters

Healthcare has become exceptionally good at responding to illness after it appears, but far less coordinated around helping people identify risk earlier. Neko Health's core product is a 1-hour, non-invasive scan that captures millions of health data points across skin, cardiovascular, blood, metabolic, and circulation markers before turning that information into clinician-guided interpretation.

The company's advantage is not simply artificial intelligence or specialized hardware. It comes from owning the entire workflow, from the scan itself to the software platform to the clinic operation, creating tighter feedback loops than a fragmented solution layered onto someone else's system.

Market Context

Preventive healthcare has evolved from an academic discussion into a more investable category as healthcare costs rise, populations age, and AI-assisted diagnostics become increasingly capable. That shift creates opportunities for companies that can turn earlier detection into a repeatable clinical and consumer experience rather than another disconnected health data dashboard.

Neko Health enters the U.S. with momentum from clinics operating in Sweden and the U.K. The expansion also illustrates a broader startup lesson: in healthcare, software alone is often insufficient when the product must simultaneously earn the trust of patients, clinicians, regulators, and investors.

The Business Lessons Behind the Funding

Founders often assume investors reward bold ideas, but institutional capital usually rewards execution that has already survived contact with reality. Neko Health's $700M Series C reflects years of product development, clinical workflow design, and operational infrastructure that make the company more difficult to replicate than a traditional digital health application.

The second lesson is that category-defining companies rarely ask how to make existing systems incrementally better. Neko Health is asking whether healthcare should be organized around maintaining health before disease escalates, a fundamentally different business premise from optimizing treatment after the fact.

What This Signals for Venture Capital and HealthTech

The financing signals continued investor conviction in companies building infrastructure around preventive medicine rather than narrow point solutions. It also demonstrates capital flowing toward businesses that combine technical differentiation with operational ownership, because controlling more of the patient experience can create a more defensible healthcare company.

For founders, the message is straightforward: technology creates attention, but integrated execution creates enterprise value. Neko Health has earned attention because of the size of its financing, but the more interesting story is the system it is building around a future where preventive care becomes mainstream rather than optional.